Molecular Insight Pharmaceuticals, Inc. To Present Interim Phase 1 Data at ASCO on Azedra in Malignant Pheochromocytoma/Paraganglioma PatientsCAMBRIDGE, Mass.--(BUSINESS WIRE)--May 16, 2008 - Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that it will present interim data at the annual meeting of the American Society for Clinical Oncology (ASCO) on its Phase I clinical trial of Azedra (Ultratrace(TM) Iobenguane I 131) in patients with malignant pheochromocytoma/paraganglioma. The trial is part of the company's program to develop Azedra for the treatment of neuroendocrine cancers. The abstract and presentation details are as follows: -0-
Abstract Title: "A phase I study of Iobenguane I 131 to evaluate MTD, efficacy and safety in patients with malignant pheochromocytoma/paraganglioma (Pheo)" Authors: M. A. Morse, J. W. Babich, N. LaFrance, K. A. Kacena, J. Gockerman, J. Moore, R. E. Coleman Abstract ID: 4605 Poster Session: Gastrointestinal (Noncolorectal) Cancer Poster Board #: 41B Date: Monday, June 2, 2008 Time: 8:00 AM - 12:00 PM Location: S Hall A1
About Molecular Insight Pharmaceuticals, Inc.
Molecular Insight Pharmaceuticals (NASDAQ: MIPI) is a biopharmaceutical company specializing in the emerging field of molecular medicine, applying innovations in the identification and targeting of disease at the molecular level to improve healthcare for patients with life-threatening diseases. The company is focused on discovering, developing and commercializing innovative, molecular radiotherapeutics and molecular imaging pharmaceuticals with initial applications in the areas of oncology and cardiology. Its lead molecular radiotherapeutic product candidates, Azedra and Onalta, are being developed for detection and treatment of cancer. The company's lead molecular imaging pharmaceutical product candidate, Zemiva, is being developed for the diagnosis of cardiac ischemia, or insufficient blood flow to the heart. In addition, the company has a growing pipeline of product candidates resulting from application of its proprietary platform technologies to new and existing compounds. Molecular Insight Pharmaceuticals is based in Cambridge, Massachusetts and its website address is: www.molecularinsight.com.
Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about the development of Azedra(TM), Onalta (TM), Zemiva(TM) and our other product candidates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Molecular Insight to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Molecular Insight undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.
Molecular Insight Pharmaceuticals, Inc.
Priscilla Harlan, 617-492-5554
Vice President, Corporate Communications
Posted: May 2008